sodium 4-methoxyphenylsulfamate | 64808-25-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: sodium 4-methoxyphenylsulfamate
• 英文别名: sodium;N-(4-methoxyphenyl)sulfamate
• CAS: 64808-25-9
• 化学式: C₇H₈NO₄S*Na
• 分子量: 225.201
• InChiKey: DKFIIPQHXRGANG-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -2.43
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  86.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  sodium 4-methoxyphenylsulfamate 在 五氯化磷 作用下， 以 苯 为溶剂， 反应 15.0h， 生成 (4-methoxyphenyl)sulfamoyl chloride
  参考文献：
  名称：

  WO2007/27454

  摘要：

  公开号：
• 作为产物：
  描述：

  氯磺酸 、 甲氧苯胺 在 sodium carbonate 作用下， 以 氯仿 、 水 为溶剂， 生成 sodium 4-methoxyphenylsulfamate
  参考文献：
  名称：

  WO2007/27454

  摘要：

  公开号：

文献信息

• The photochemistry of para-substituted phenylsulphamates—photo-Fries rearrangements
  作者：John M. Lally、William J. Spillane

  DOI：10.1039/p29910000803

  日期：——

  XC6H4NHSO3Na [XH (1a), CH3(1b), F (1c), Cl (1d), Br (1e) and NO2(1f)] in degassed methanolic solutions has been examined. For 1a and 1b photo-Fries type rearrangements to sulphonic acids and photodegradation to anilines have been observed. The halogenosulphamates 1c–1e do not rearrange but degrade to anilines and are photosolvolysed to p-methoxyphenylsulphamic acid. No notable spectral changes took place during

  一系列对位取代的苯磺酸盐，XC 6 H 4 NHSO 3 Na [X H（1a），CH 3（1b），F（1c），Cl（1d），Br（1e）和已检查了脱气甲醇溶液中的NO 2（1f）]。对于1a和1b，已经观察到光爆型重排成磺酸和被光降解成苯胺。卤代硫酸盐1c – 1e不会重新排列，但会降解为苯胺，并被光解为苯胺。对甲氧基苯基硫酸。在1f的辐射中，在相对较长的时间内没有发生明显的光谱变化。对1b的底物浓度研究，自由基清除，敏化和淬灭实验表明，如先前对1a的发现，其光解涉及分子内自由基机理，并涉及两个三重态。
• Chemical compounds
  申请人：Ratcliffe James Andrew

  公开号：US20050009831A1

  公开（公告）日：2005-01-13

  The present invention concerns compounds of general formula (I): in which: R 1 represents hydrogen, R 4 , —C(═Y)—NHR 4 , —SO 2 NHR 4 , —C(=Z 1 )—R 4 , —SO 2 —R 4 or —C(=Z 1 )—OR 4 ; R 2 represents hydrogen, cyano, halogen or —C≡C—R 5 ; R 3 represents hydrogen, acyl, alkoxycarbonyl, alkyl, aroyl, aryl, aryloxycarbonyl, carboxy, cycloalkenyl, cycloalkyl, heteroaroyl, heteroaryl, heterocycloalkyl or —C(═O)—NY 1 Y 2 ; R 4 represents optionally substituted alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl or heteroaryl R 5 represents hydrogen or alkyl; R 6 represents alkyl, acyl, alkoxycarbonyl, alkylsulfonyl, aryl, arylsulfonyl, aroyl, cycloalkyl, cycloalkenyl, heteroaryl, heteroarylsulfonyl, heteroaroyl and heterocycloalkyl; R 7 represents optionally substituted alkyl, cycloalkyl or cycloalkylalkyl, R 8 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; R 9 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R 10 represents hydrogen or lower alkyl; R 11 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; or alkyl optionally substituted by —NY 1 Y 2 ; R 12 represents aryl or heteroaryl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted Y represents O, S or NCN; Y 1 and Y 2 (Y 3 and Y 4 ) are independently in particular hydrogen, alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocycloalkyl; or the group —NY 1 Y 2 may form 5-7 membered ring or the group —NY 3 Y 4 (—NY 5 Y 6 ) may form a cyclic amine; Z (Z 1 ) represents O or S; Z 2 represents O or S(O) p ; n is zero or an integer 1 or 2; m is 1 or 2; p is 1 or 2; and their corresponding N-oxides, their prodrugs; their pharmaceutically acceptable salts and solvates (e.g. hydrates), also together with one or more pharmaceutically acceptable carriers or excipients, such novel indolizines derivatives with inhibitory effects towards kinase proteins and especially for use for preventing or treating diseases that may be modulated by the inhibition of such kinase proteins and particularly solid tumours.

  本发明涉及通式（I）的化合物： 其中： R1代表氢，R4，—C（═Y）—NHR4，—SO2NHR4，—C（=Z1）—R4，—SO2—R4或—C（=Z1）—OR4； R2代表氢，氰基，卤素或—C≡C—R5； R3代表氢，酰基，烷氧羰基，烷基，芳酰基，芳基，芳氧羰基，羧基，环烯基，环烷基，杂芳酰基，杂芳基，杂环烷基或—C（═O）—NY1Y2； R4代表可选取代的烷基，环烷基，环烯基，杂环烷基，芳基或杂芳基； R5代表氢或烷基； R6代表烷基，酰基，烷氧羰基，烷基磺酰基，芳基，芳基磺酰基，芳酰基，环烷基，环烯基，杂芳基，杂芳基磺酰基，杂芳酰基和杂环烷基； R7代表可选取代的烷基，环烷基或环烷基烷基； R8代表氢，烷基，烯基，芳基，芳基烷基，杂芳基或杂芳基烷基； R9代表烷基，芳基，芳基烷基，环烷基，环烷基烷基，杂芳基，杂芳基烷基，杂环烷基或杂环烷基烷基； R10代表氢或较低的烷基； R11代表烷基，芳基，芳基烷基，环烷基，环烷基烷基，杂芳基，杂芳基烷基，杂环烷基或杂环烷基烷基；或可选取代的烷基，被—NY1Y2取代； R12代表芳基或杂芳基；或可选取代的烷基，环烷基，环烷基烷基，杂环烷基或杂环烷基烷基； Y代表O，S或NCN； Y1和Y2（Y3和Y4）特别是独立的氢，烷基，芳基，环烷基，环烯基，杂芳基或杂环烷基；或该基团—NY1Y2可能形成5-7成员环或该基团—NY3Y4（—NY5Y6）可能形成一个环状胺； Z（Z1）代表O或S； Z2代表O或S（O）p； n为零或整数1或2； m为1或2； p为1或2； 以及它们对应的N-氧化物，它们的前药；它们的药物可接受的盐和溶剂化合物（例如水合物），还包括一个或多个药物可接受的载体或赋形剂，这种新的吲哚嗪衍生物具有对激酶蛋白的抑制作用，特别是用于预防或治疗可能通过抑制这种激酶蛋白而调节的疾病，特别是固体肿瘤。
• JNK INHIBITORS
  申请人：Nemecek Conception

  公开号：US20070238734A1

  公开（公告）日：2007-10-11

  The present invention concerns compounds of general formula (I): in which the substituents are as described herein.

  本发明涉及一般式（I）的化合物： 其中取代基如本文所述。
• Heterocyclic dihydropyrimidine compounds
  申请人：Han Wei

  公开号：US20070203157A1

  公开（公告）日：2007-08-30

  Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the K v 1 subfamily of voltage gated K + channels, especially inhibitors K v 1.5 which has been linked to the ultra-rapidly activating delayed rectifier, which have the structure stereoisomers including enantiomers thereof and diastereomers thereof, or a pharmaceutically acceptable salt thereof, wherein Q is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl or which is aryl, substituted aryl, heteroaryl or substituted heteroaryl; R 3 is wherein R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are defined herein. Methods of using such compounds in the prevention and treatment of arrhythmia and I Kur -associated conditions, and pharmaceutical compositions containing such compounds are also provided.

  新型杂环二氢嘧啶化合物，可用作钾通道功能抑制剂（尤其是Kv1亚家族电压门控K+通道的抑制剂，尤其是与超快速激活延迟整流器相关的Kv1.5的抑制剂），其结构包括立体异构体，包括其对映异构体和顺反异构体，或其药学上可接受的盐，其中Q为烷基，取代烷基，环烷基，取代环烷基，环杂烷基，取代环杂烷基或芳基，取代芳基，杂芳基或取代杂芳基；R3为其中R1、R2、R4、R5、R6、R7、R8、R9和R10在此定义。还提供了使用这种化合物预防和治疗心律失常和IKur相关疾病的方法以及含有这种化合物的制药组合物。
• Substituted pyrazolo[1,5-a]pyrimidines as potassium channel activators
  申请人：Bristol-Myers Squibb Company

  公开号：US07507730B2

  公开（公告）日：2009-03-24

  Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier, which have the structure stereoisomers including enantiomers thereof and diastereomers thereof, or a pharmaceutically acceptable salt thereof, wherein Q is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl or which is aryl, substituted aryl, heteroaryl or substituted heteroaryl; R3 is wherein R1, R2, R4, R5, R6, R7, R8, R9 and R10 are defined herein. Methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds are also provided.

  新型杂环二氢嘧啶化合物，可用作钾通道功能的抑制剂（特别是Kv1亚家族的电压门控K+通道的抑制剂，特别是与超快速激活延迟整流器相关的Kv1.5抑制剂），其结构包括立体异构体，包括其对映异构体和顺反异构体，或其药学上可接受的盐，其中Q是烷基，取代烷基，环烷基，取代环烷基，环杂烷基，取代环杂烷基或芳基，取代芳基，杂芳基或取代杂芳基; R3为其中R1、R2、R4、R5、R6、R7、R8、R9和R10在此定义。还提供了使用这些化合物预防和治疗心律失常和IKur相关疾病的方法，以及含有这些化合物的制药组合物。